Long-Term Lithium Therapy for Bipolar Disorder

Systematic Review and Meta-Analysis of Randomized Controlled Trials

John R. Geddes, Sally Burgess, Keith Hawton, Kay Jamison, Guy M. Goodwin

Research output: Contribution to journalArticle

Abstract

Objective: The authors sought to determine the efficacy and acceptability of lithium for relapse prevention in bipolar disorder. Method: A systematic review and meta-analysis of randomized controlled trials comparing lithium with placebo in the long-term treatment of bipolar disorders was conducted. Data were obtained from searching the registers of the Cochrane Collaboration; reviewing reference lists, journals, and conference abstracts; and contacting authors, experts, and pharmaceutical companies. Outcomes investigated included risk of relapse (manic, depressive, and total) as well as risk of specific adverse effects and total withdrawal rates. Results: Five randomized controlled trials (770 participants) were included. Lithium was more effective than placebo in preventing all relapses (random effects relative risk=0.65, 95% Cl=0.50 to 0.84) and manic relapses (relative risk=0.62, 95% Cl=0.40 to 0.95). The protective effect of lithium on depressive relapses was smaller and was less robust (relative risk= 0.72, 95% Cl=0.49 to 1.07). Conclusions: Lithium treatment reduces the risk of relapse in bipolar disorder. The preventive effect is clear for manic episodes, although it is equivocal for depressive episodes.

Original languageEnglish (US)
Pages (from-to)217-222
Number of pages6
JournalAmerican Journal of Psychiatry
Volume161
Issue number2
DOIs
StatePublished - Feb 2004
Externally publishedYes

Fingerprint

Bipolar Disorder
Lithium
Meta-Analysis
Randomized Controlled Trials
Recurrence
Therapeutics
Placebos
Secondary Prevention
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Long-Term Lithium Therapy for Bipolar Disorder : Systematic Review and Meta-Analysis of Randomized Controlled Trials. / Geddes, John R.; Burgess, Sally; Hawton, Keith; Jamison, Kay; Goodwin, Guy M.

In: American Journal of Psychiatry, Vol. 161, No. 2, 02.2004, p. 217-222.

Research output: Contribution to journalArticle

Geddes, John R. ; Burgess, Sally ; Hawton, Keith ; Jamison, Kay ; Goodwin, Guy M. / Long-Term Lithium Therapy for Bipolar Disorder : Systematic Review and Meta-Analysis of Randomized Controlled Trials. In: American Journal of Psychiatry. 2004 ; Vol. 161, No. 2. pp. 217-222.
@article{6b52bd8755604a0e96a6f557425801c1,
title = "Long-Term Lithium Therapy for Bipolar Disorder: Systematic Review and Meta-Analysis of Randomized Controlled Trials",
abstract = "Objective: The authors sought to determine the efficacy and acceptability of lithium for relapse prevention in bipolar disorder. Method: A systematic review and meta-analysis of randomized controlled trials comparing lithium with placebo in the long-term treatment of bipolar disorders was conducted. Data were obtained from searching the registers of the Cochrane Collaboration; reviewing reference lists, journals, and conference abstracts; and contacting authors, experts, and pharmaceutical companies. Outcomes investigated included risk of relapse (manic, depressive, and total) as well as risk of specific adverse effects and total withdrawal rates. Results: Five randomized controlled trials (770 participants) were included. Lithium was more effective than placebo in preventing all relapses (random effects relative risk=0.65, 95{\%} Cl=0.50 to 0.84) and manic relapses (relative risk=0.62, 95{\%} Cl=0.40 to 0.95). The protective effect of lithium on depressive relapses was smaller and was less robust (relative risk= 0.72, 95{\%} Cl=0.49 to 1.07). Conclusions: Lithium treatment reduces the risk of relapse in bipolar disorder. The preventive effect is clear for manic episodes, although it is equivocal for depressive episodes.",
author = "Geddes, {John R.} and Sally Burgess and Keith Hawton and Kay Jamison and Goodwin, {Guy M.}",
year = "2004",
month = "2",
doi = "10.1176/appi.ajp.161.2.217",
language = "English (US)",
volume = "161",
pages = "217--222",
journal = "American Journal of Psychiatry",
issn = "0002-953X",
publisher = "American Psychiatric Association",
number = "2",

}

TY - JOUR

T1 - Long-Term Lithium Therapy for Bipolar Disorder

T2 - Systematic Review and Meta-Analysis of Randomized Controlled Trials

AU - Geddes, John R.

AU - Burgess, Sally

AU - Hawton, Keith

AU - Jamison, Kay

AU - Goodwin, Guy M.

PY - 2004/2

Y1 - 2004/2

N2 - Objective: The authors sought to determine the efficacy and acceptability of lithium for relapse prevention in bipolar disorder. Method: A systematic review and meta-analysis of randomized controlled trials comparing lithium with placebo in the long-term treatment of bipolar disorders was conducted. Data were obtained from searching the registers of the Cochrane Collaboration; reviewing reference lists, journals, and conference abstracts; and contacting authors, experts, and pharmaceutical companies. Outcomes investigated included risk of relapse (manic, depressive, and total) as well as risk of specific adverse effects and total withdrawal rates. Results: Five randomized controlled trials (770 participants) were included. Lithium was more effective than placebo in preventing all relapses (random effects relative risk=0.65, 95% Cl=0.50 to 0.84) and manic relapses (relative risk=0.62, 95% Cl=0.40 to 0.95). The protective effect of lithium on depressive relapses was smaller and was less robust (relative risk= 0.72, 95% Cl=0.49 to 1.07). Conclusions: Lithium treatment reduces the risk of relapse in bipolar disorder. The preventive effect is clear for manic episodes, although it is equivocal for depressive episodes.

AB - Objective: The authors sought to determine the efficacy and acceptability of lithium for relapse prevention in bipolar disorder. Method: A systematic review and meta-analysis of randomized controlled trials comparing lithium with placebo in the long-term treatment of bipolar disorders was conducted. Data were obtained from searching the registers of the Cochrane Collaboration; reviewing reference lists, journals, and conference abstracts; and contacting authors, experts, and pharmaceutical companies. Outcomes investigated included risk of relapse (manic, depressive, and total) as well as risk of specific adverse effects and total withdrawal rates. Results: Five randomized controlled trials (770 participants) were included. Lithium was more effective than placebo in preventing all relapses (random effects relative risk=0.65, 95% Cl=0.50 to 0.84) and manic relapses (relative risk=0.62, 95% Cl=0.40 to 0.95). The protective effect of lithium on depressive relapses was smaller and was less robust (relative risk= 0.72, 95% Cl=0.49 to 1.07). Conclusions: Lithium treatment reduces the risk of relapse in bipolar disorder. The preventive effect is clear for manic episodes, although it is equivocal for depressive episodes.

UR - http://www.scopus.com/inward/record.url?scp=1642527883&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1642527883&partnerID=8YFLogxK

U2 - 10.1176/appi.ajp.161.2.217

DO - 10.1176/appi.ajp.161.2.217

M3 - Article

VL - 161

SP - 217

EP - 222

JO - American Journal of Psychiatry

JF - American Journal of Psychiatry

SN - 0002-953X

IS - 2

ER -